Skip to main content
Premium Trial:

Request an Annual Quote

Roy Baynes

Natera has appointed Roy Baynes to its board of directors. Baynes is chief medical officer at Merck and senior vice president and head of global clinical development at Merck Research Laboratories. He has also held several roles at Gilead Sciences and Amgen and is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research. Prior to joining industry, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.